Citations (14)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (2)
Michael Kukulka, Corey Eisenberg & Sai Nudurupati. (2011) Comparator pH study to evaluate the single-dose pharmacodynamics of dual delayed-release dexlansoprazole 60 mg and delayed-release esomeprazole 40 mg. Clinical and Experimental Gastroenterology 4, pages 213-220.
Read now
Read now
Keith G Tolman, Jane Chandramouli & John C Fang. (2000) Proton pump inhibitors in the treatment of gastro-oesophageal reflux disease. Expert Opinion on Pharmacotherapy 1:6, pages 1171-1194.
Read now
Read now
Articles from other publishers (12)
Charles Muller, Natalie Tapaskar & Robert T. Kavitt. 2020. Foregut Surgery. Foregut Surgery
121
143
.
Richat Abbas, Cathie Leister & Daryl Sonnichsen. (2013) A Clinical Study to Examine the Potential Effect of Lansoprazole on the Pharmacokinetics of Bosutinib when Administered Concomitantly to Healthy Subjects. Clinical Drug Investigation 33:8, pages 589-595.
Crossref
Crossref
Yoshiyuki Watanabe, Naoyuki Kato, Tadateru Maehata, Masaru Okamoto, Takashi Tsuda, Santa Hattori, Shunichi Yamauchi, Kazuhiko Fujita, Satoshi Baba, Shinichi Nakaya, Hiroyuki Inaba, Satoshi Kitajima, Michihiro Suzuki, Hirohumi Niwa & Fumio Itoh. (2006) Safer endoscopic gastric mucosal resection: Preoperative proton pump inhibitor administration. Journal of Gastroenterology and Hepatology 21:11, pages 1675-1680.
Crossref
Crossref
J. P. Galmiche, S. Sacher‐Huvelin, S. Bruley des Varannes, F. Vavasseur, A. Taccoen, P. Fiorentini & M. Homerin. (2005) A comparative study of the early effects of tenatoprazole 40 mg and esomeprazole 40 mg on intragastric pH in healthy volunteers. Alimentary Pharmacology & Therapeutics 21:5, pages 575-582.
Crossref
Crossref
Hidekazu Suzuki, Tatsuhiro Masaoka, Yuriko Minegishi, Yuichiro Motosugi, Soichiro Miura & Hiromasa Ishii. (2008) Lansoprazole promotes gastric mucosal cell proliferation and migration by activating p44/p42 mitogen‐activated protein kinase. Wound Repair and Regeneration 12:1, pages 93-99.
Crossref
Crossref
D. Pantoflickova, G. Dorta, M. Ravic, P. Jornod & A. L. Blum. (2003) Acid inhibition on the first day of dosing: comparison of four proton pump inhibitors. Alimentary Pharmacology & Therapeutics 17:12, pages 1507-1514.
Crossref
Crossref
J.L.C.M Dorne, K Walton & A.G Renwick. (2003) Polymorphic CYP2C19 and N-acetylation: human variability in kinetics and pathway-related uncertainty factors. Food and Chemical Toxicology 41:2, pages 225-245.
Crossref
Crossref
RL Bown. (2002) AN OVERVIEW OF THE PHARMACOLOGY, EFFICACY, SAFETY AND COST‐EFFECTIVENESS OF LANSOPRAZOLE. International Journal of Clinical Practice 56:2, pages 132-139.
Crossref
Crossref
J.‐Q. Huang, D. R. Goldwater, A. B. R. Thomson, S. A. Appelman, S. Sridhar, C. F. James, Y.‐L. Chiu, B. L. Pilmer, R. G. Keith & R. H. Hunt. (2002) Acid suppression in healthy subjects following lansoprazole or pantoprazole. Alimentary Pharmacology & Therapeutics 16:3, pages 425-433.
Crossref
Crossref
B.R. Yacyshyn & A.B.R. Thomson. (2002) The Clinical Importance of Proton Pump Inhibitor Pharmacokinetics. Digestion 66:2, pages 67-78.
Crossref
Crossref
Müller, Göksu, Fuchs, Schlüter & Simon. (2001) Initial potency of lansoprazole and omeprazole tablets on pentagastrin‐stimulated gastric acid secretion—a placebo‐controlled study in healthy volunteers. Alimentary Pharmacology & Therapeutics 14:9, pages 1225-1229.
Crossref
Crossref
F. Vicari, Maryse Joubert-Collin & F. Perie. (1999) Efficacité et tolérance du lansoprazole 15 mg dans le traitement des symptômes du RGO. Comparaison au cisapride 20 mgEfficacy and safety of lansoprazole 15 mg in the treatment of GOR symptoms. Comparison to cisapride 20 mg. Acta Endoscopica 29:5, pages 607-615.
Crossref
Crossref